3SBio
在场
3SBio 是一家在股票代码 1530 (HK) 下上市的公司。
高管
查看带有其 10 名主要高管的组织结构图
3SBio 搜索最多的简介
- Jing Lou, Executive Chairman Of The Board and Chief Executive Offi...
- Tianruo Pu, Independent Non-Executive Director
- Joo Yeow Ng, Non-Executive Independent Director
高管在3SBio变化
- Bin Huang, Non-Executive Director, 已经离开公司 (新闻发布的2024六月27号).
- Dan Zhang, Independent Non-Executive Director, 将于 20246月25 退休 (新闻发布的2024四月23号).
创建提醒
跟踪 3SBio 的高管变动
药店
3SBio 拥有 1,842 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。
Popular M&A news in 药店
- BeiGene将改名为BeOne Medicines。 (公布2024十一月15号).
- GlycoMimetics and Crescent Biopharma have announced they will merge (公布2024十一月15号)..
- Grace Therapeutics将在Oct 25, 2024将其名称改为Grace Therapeutics。 (公布2024十月27号).
药店 行业的其他推荐联系人
消息
3SBio 的最新新闻稿
- 3SBio Unveils 2024 Interim Results: Revenue Up 16% YoY, Autoimmune Pipeline Poised for a Promising Phase
- 3SBio reveals 2023 annual results: Revenue surges by 13.8% year on year, with pipelines to reap the rewards
- 3SBio announces 2022 annual results, with revenue rising 7.5% year on year and normalized net profit attributable to parents jumping 25.2%
- 3SBio announces 2022 interim results, with net profit attributable to owners of the parents continuing to grow despite COVID-19 and cash hitting new record high
- 3SBio announces 2021 annual results, with net profit attributable to owns of the parents almost doubling under accelerated growth of diversified businesses
- 3SBIO
- 3SBIO
- View more press releases Close
通过电子邮件
